The 4th Bioindustry Conference discussed the topics related to industrial planning

Business Association, June 24th, "12th Five-Year Plan for the Revitalization of the Biopharmaceutical Industry"(
called "Planning") preparation of the work is about to be closedThis is the National Development and Reform Commission deputy director Zhang Xiaoqiang at the 4th China Biological Industry Conference revealedThe reporter of the Medical Economic Daily also learned that during the General Assembly, the National Development and Reform Commission, planning experts and business representatives held a closed-door discussion on the Planin the past, has been "12th Five-Year" bio-pharmaceutical industry revitalization plan in the nearly two months is expected to be announcedNews, triggered the industry on the future of the domestic biopharmaceutical industry analysis and predictionReporters at the conference found that in the recent industry trend is frequent, enterprises on the biopharmaceutical industry related policies more concernthanly than beforevaccines and other industries have more advantages
in order to implement the National Medium- and Long-Term Science and Technology Development Plan(
2
006-
20
2
000) to accelerate the cultivation of the biological industry has risen to become a national strategic emerging industry Compared with the traditional pharmaceutical industry, the average annual growth rate of global bio
pharmaceutical has greatly exceeded the average annual growth rate of the global pharmaceutical industry A clear trend is that biologics account for a growing proportion of prescription drug sales at large pharmaceutical companies In China, the conversion rate of biomedical research and development results is only about 10% The problem of industrialization is imminent
"From foreign experience, the proportion of investment in research and development, pilot and industrialization is about 1:10:100 In this way, the late industrialization investment is the largest, but also the most critical link Feng Fei, head of the Industrial and Economic Research Department of the Development Research Center of the State Council, said He further pointed out that in the process of promoting the industrialization of biomedicine in China, new vaccines, biotechnology drugs and small molecular drugs, modern Chinese medicine and plant medicine and other sub-industries have the advantageof to realize industrialization the country to actively build financing platform
in recent years, before the national industrial planning has not been introduced, all over the country have invested heavily in the biopharmaceutical industry projects However, from a practical point of view, many local industries positioned in the same, and even have a circle
"It is very important that the state set up a bio-industrialization fund to guide the construction orientation of the industrialization platform by establishing a market-oriented venture capital mechanism Feng Fei said that the development model of innovative bio-industry should give full play to the advantages of the national bio-industry base and set up a bio-industry financing platform in a market-oriented mode of operation said: "We will strive to support the country's major new drug creation, as well as AIDS, viral hepatitis and other major infectious diseaseprevention and control projects, focusing on supporting the industrialization of biotechnology, focus ingress on technological innovation and industrial upgrading." "
the person in charge also revealed that this year will study and participate in the establishment of venture capital guidance fund, with relevant ministries and related units, actively promote the establishment of bio-industry development fund, play the role of high-tech industry alliance, establish the government, research institutes, enterprises
, banks and other departments of cooperation mechanism, to build a high-tech development system adapted to the characteristics of the biological industry drug prices to affect the nerves of enterprises
the recent "drug price management methods (
draft for comments)" (
called "Measures") in the industry hotly debated Biopharmaceutical companies are generally concerned about the specific criteria for drug pricing and the spread rate of drug circulation in the Measures Reporters in the General Assembly exhibition area visit found that many biopharmaceutical enterprises have expressed concern about the future drug price policy a well-known bio-enterprise person told reporters that if the real implementation of the Measures, many biopharmaceutical enterprises will be difficult to sustain Compared with the pricing advantages enjoyed by foreign biological products, the pricing of similar products in China is generally lower, but its production costs are generally relatively high, which will weaken the sustainable development of biopharmaceutical enterprises
"It is hoped that appropriate consideration will be given to the price of biological drugs in both the Measures and the bio-industry revitalization plan 'One size fits all' will only make the industry develop more rigid, less vitality The person said , companies trying to get involved in the field of biologics feel the same way Qianjin Pharmaceutical senior engineer Teng Wei believes that if the circulation mark-up rate and profit margin are set up upper limit, will inevitably force the middle link of circulation, thus triggering the pharmaceutical industry's price reduction storm Although from the production link cost rate and sales cost rate of the highest accounting standards, reflects the idea of encouraging innovation, encouraging Chinese medicine and biological medicine, but Teng Wei is concerned that "biomedicine as a high-risk, high-input high-tech industry, simply cost pricing, innovative enterprises will certainly hurt a lot, enterprises are unable to compensate for the huge investment in research and development, innovation will be hindered, and ultimately affect the overall progress of the industry." the next page of the the next page, the of the 2